Logo

TVGNW

Tevogen Bio Holdings Inc.

TVGNW

Tevogen Bio Holdings Inc. • NASDAQ
$0.04 ▲ 7.09% (+0.00)
Market Cap $9.08 M
52w High $0.04
52w Low $0.04
Dividend Yield 0%
P/E 0
Volume 5.81K
Outstanding Shares 207.42M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $5.702M ▲ $-5.727M ▼ 0% $-0.03 ▲ $-5.637M ▼
Q2-2025 $0 $5.154M ▼ $-5.504M ▲ 0% $-0.031 ▲ $-5.175M ▲
Q1-2025 $0 $10.251M ▲ $-10.367M ▼ 0% $-0.065 ▼ $-10.237M ▼
Q4-2024 $0 $9.26M ▲ $-9.25M ▼ 0% $-0.052 ▼ $-9.325M ▼
Q3-2024 $0 $5.984M $-5.909M 0% $-0.035 $-5.77M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.037M ▲ $4.494M ▲ $12.318M ▼ $-7.824M ▲
Q2-2025 $685.229K ▼ $4.269M ▲ $13.754M ▲ $-9.485M ▼
Q1-2025 $1.975M ▲ $4.073M ▲ $11.793M ▲ $-7.72M ▼
Q4-2024 $1.283M ▼ $3.462M ▼ $10.136M ▼ $-6.674M ▼
Q3-2024 $2.331M $4.289M $10.48M $-6.19M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.727M ▼ $-3.65M ▼ $0 $4.001M ▲ $351.865K ▲ $-3.65M ▼
Q2-2025 $-5.504M ▲ $-3.19M ▲ $0 $1.9M ▼ $-1.29M ▼ $-3.19M ▲
Q1-2025 $-10.367M ▼ $-3.308M ▼ $0 $4M ▲ $691.937K ▲ $-3.308M ▼
Q4-2024 $-9.25M ▼ $-3.048M ▲ $0 $2M ▼ $-1.048M ▼ $-3.048M ▲
Q3-2024 $-5.884M $-3.805M $0 $5M $1.195M $-3.805M

Five-Year Company Overview

Income Statement

Income Statement Tevogen Bio is still a pure development-stage biotech: it has essentially no product revenue yet and its costs are mostly research, overhead, and public-company expenses. Losses are modest in absolute size but consistent, reflecting ongoing spending without any commercial offset. The pattern over the last few years is choppy, which is typical for a very small company where one-time items can swing results. Overall, the income statement shows an early clinical company investing ahead of any revenue, with the clear expectation that future product success would need to justify today’s losses.

Balance Sheet

Balance Sheet The balance sheet looks very lean and somewhat fragile. Total assets have shrunk sharply from earlier levels, cash is very limited, and recent figures point to negative equity, meaning accumulated losses now exceed the book value of assets. Prior debt has largely disappeared, which reduces financial obligations but likely came alongside dilution or asset runoff. The current profile suggests a company that will almost certainly need fresh capital to support its pipeline and operations, with limited cushion if funding conditions tighten.

Cash Flow

Cash Flow Cash flow is straightforward: money flows out, not in. Operating cash flow has been consistently negative, reflecting payroll, research, and overhead, with no real offset from revenue. Capital spending appears minimal, so cash burn is driven mainly by operating activities rather than large equipment or facility builds. This is typical for an asset-light, clinical-stage biotech, but it also underlines dependence on external funding rounds or partnerships to keep the programs moving forward.

Competitive Edge

Competitive Edge Tevogen’s competitive story rests more on science than on current scale. It operates in the crowded and fast-moving immunotherapy space, but focuses on off-the-shelf, genetically unmodified T‑cell therapies, aiming to sidestep some of the complexity, cost, and safety issues of current personalized and gene-modified approaches. The claimed advantages include simpler logistics, potentially lower treatment costs, and a broader patient reach through allogeneic products. At the same time, it competes against much larger, better-funded biotech and pharma companies, faces rapid scientific change, and is still early in clinical validation, so its position is promising but unproven and highly dependent on trial outcomes and regulatory success.

Innovation and R&D

Innovation and R&D Innovation is the core of Tevogen’s value proposition. Its ExacTcell platform aims to create off-the-shelf T‑cell products that are not genetically altered, targeting multiple viral or tumor proteins to maintain effectiveness as diseases evolve. The lead program started in COVID and Long COVID, with additional candidates in virus-driven cancers, liver cancer risk reduction, oncology, and multiple sclerosis. On top of that, the company is layering in AI-based tools (PredicTcell and partnerships with major cloud and data firms) to speed up target discovery and design. The R&D strategy is ambitious and diversified for a small firm, but also capital‑intensive and high risk, with long timelines and many clinical and regulatory hurdles still ahead.

Summary

Tevogen Bio looks like a classic early-stage biotech: scientifically ambitious, commercially pre‑revenue, and financially thin. The financial statements show ongoing losses, shrinking assets, and negative equity, which together imply a strong need for additional funding and a meaningful risk if capital markets or partners are not available on acceptable terms. On the opportunity side, the company is pursuing a distinctive approach to T‑cell therapy—off‑the‑shelf, unmodified cells with an emphasis on affordability and scalability, backed by owned intellectual property and AI‑enabled discovery. The key tension is clear: the scientific and platform story is interesting and potentially disruptive, but it sits on top of a very early, high‑uncertainty, and capital‑dependent financial base where future outcomes are likely to be driven more by clinical and regulatory milestones than by any current financial metrics.